Animal Pain Management: Approaches and Best Practices

Pain management in animals has moved far beyond the old assumption that animals either don't feel pain the way humans do, or that expressing pain might somehow help them recover. The science settled that debate decisively. This page covers the major pharmacological and non-pharmacological approaches veterinary clinicians use to assess and treat pain across species, the regulatory frameworks governing controlled substances in veterinary settings, and the clinical decision points that distinguish acute from chronic pain protocols.

Definition and scope

Animal pain management is the clinical discipline concerned with recognizing, quantifying, and treating nociceptive, inflammatory, and neuropathic pain in non-human patients — from household dogs and cats to horses, livestock, and exotic species. The American Veterinary Medical Association (AVMA) formally recognizes pain recognition and alleviation as a core veterinary obligation under its animal welfare policy framework.

The scope is wider than it might appear. Pain management intersects with veterinary anesthesiology, veterinary surgery, veterinary oncology, and veterinary rehabilitation and physical therapy. It applies at every life stage — from neonatal procedures where pain responses are often underestimated, to end-of-life care where it overlaps directly with palliative protocols. The regulatory context for veterinary medicine also shapes what analgesics clinicians can prescribe, stock, and administer, particularly for opioids and Schedule II controlled substances governed by the Drug Enforcement Administration (DEA) under the Controlled Substances Act.

How it works

Pain assessment is the necessary first step, and it is harder in animals than the phrase "just watch the patient" suggests. Validated tools exist for this purpose. For dogs, the Glasgow Composite Measure Pain Scale (GCMPS) — developed at the University of Glasgow — assigns scores across six behavioral categories including mobility, vocalization, and facial expression, with a short form validated for clinical use. The Feline Grimace Scale (FGS), developed at Université de Montréal and validated in a 2019 study published in Scientific Reports, scores five facial action units on a 0–2 scale, producing a maximum pain score of 10.

Once pain is assessed, treatment follows a multimodal approach — the deliberate stacking of analgesic mechanisms to achieve better pain control at lower doses of any single drug. The major pharmacological categories are:

Opioids — mu-agonists such as morphine, methadone, and hydromorphone for moderate-to-severe pain; partial agonists such as buprenorphine for mild-to-moderate pain. All require DEA Schedule II or III registration for veterinary dispensing.
Non-steroidal anti-inflammatory drugs (NSAIDs) — the most widely used analgesics in small animal practice; meloxicam and carprofen are labeled for dogs; only meloxicam has a single-dose feline label in the US (the FDA's Center for Veterinary Medicine regulates species-specific labeling).
Alpha-2 adrenergic agonists — dexmedetomidine and xylazine, frequently used perioperatively for sedation and analgesia, particularly in equine and large animal settings.
N-methyl-D-aspartate (NMDA) receptor antagonists — ketamine at sub-anesthetic doses reduces central sensitization and wind-up pain.
Gabapentinoids — gabapentin and pregabalin address neuropathic pain and are increasingly used in chronic pain protocols for dogs and cats.
Local anesthetics — lidocaine and bupivacaine via nerve blocks, wound soakers, or intravenous constant rate infusion (CRI).

Non-pharmacological modalities — acupuncture, laser therapy (photobiomodulation), physical rehabilitation, and transcutaneous electrical nerve stimulation (TENS) — are supported by a growing evidence base and often integrated into chronic pain plans, particularly for osteoarthritis.

Common scenarios

Osteoarthritis is the most prevalent chronic pain condition in companion animals. An estimated 20% of dogs over age 1 show clinical signs of osteoarthritis, according to data cited by the Orthopedic Foundation for Animals (OFA). In cats, radiographic evidence of degenerative joint disease appears in more than 90% of cats over age 12, per research published in Veterinary Radiology & Ultrasound.

Acute perioperative pain represents a second major scenario — structured protocols govern pre-emptive analgesia (administered before incision), intraoperative CRIs, and postoperative multimodal regimens. Cancer pain, dental pain (covered in depth under veterinary dentistry), trauma, and intervertebral disc disease round out the high-volume presentations. In livestock and food animal species, pain management also triggers regulatory scrutiny around drug withdrawal times and food safety, a domain monitored by the FDA's Center for Veterinary Medicine and USDA food safety programs.

Decision boundaries

Three distinct clinical decisions shape every pain management plan.

Acute vs. chronic: Acute pain — post-surgical, traumatic, procedural — typically resolves as tissue heals and warrants short-duration, higher-intensity protocols. Chronic pain, such as osteoarthritis or neuropathic conditions, requires long-term management with attention to drug safety profiles over months or years. NSAIDs require periodic renal and hepatic monitoring in chronic cases; the AVMA recommends baseline bloodwork before initiating long-term NSAID therapy.

Species-specific limits: Cats metabolize drugs differently from dogs. Acetaminophen is lethal to cats and toxic to dogs at therapeutic human doses. Many NSAIDs labeled for dogs carry no feline label in the US. Horses, ruminants, and birds each present distinct pharmacokinetic profiles that make cross-species extrapolation genuinely risky — not merely cautious.

Severity tiering: Mild pain (e.g., minor soft-tissue procedures) typically warrants NSAIDs ± local anesthetics. Moderate pain adds an opioid or alpha-2 agonist. Severe or refractory pain triggers full multimodal protocols including NMDA antagonists and possibly referral to a board-certified veterinary specialist in anesthesiology or internal medicine. The broader landscape of what veterinary care covers across these decisions is outlined at the veterinary authority index.

References

📜 1 regulatory citation referenced · 🔍 Monitored by ANA Regulatory Watch · View update log